Atara BiotherapeuticsATRA +3.65%29 Days Payable is 281.11 as of Mar. 2026, which is 302% above its 10-year median of 69.94. GuruFocus rates ATRA with a GF Score™ of 29/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 707 Biotechnology companies, Atara Biotherapeutics ranks better than 72.84% on this metric.
Atara Biotherapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Atara Biotherapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atara Biotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Atara Biotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atara Biotherapeutics (ATRA) has a Days Payable of 281.11 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atara Biotherapeutics and its competitors. This is 302% above median its historical median of 69.94. Over the past decade, Atara Biotherapeutics' Days Payable has ranged from 38.66 to 344.08. According to the industry distribution chart, Atara Biotherapeutics ranks #192 out of 707 companies in the Biotechnology industry, placing it in the top 27.2%.
Is Atara Biotherapeutics' Days Payable too high?
Atara Biotherapeutics' current Days Payable of 281.11 is 302% above median its 10-year median of 69.94. Over the past 10 years, this metric has ranged from a low of 38.66 to a high of 344.08. The Biotechnology industry median Days Payable is 113.76. Atara Biotherapeutics' value of 281.11 is 147.1% above this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #192 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atara Biotherapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Days Payable compare to RNTX and IBIO?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #192 out of 707 companies for Days Payable. This puts Atara Biotherapeutics in the upper half of its industry. The industry median Days Payable is 113.76. Atara Biotherapeutics' value of 281.11 is 147.1% above this benchmark. Historically, Atara Biotherapeutics' own Days Payable has ranged from 38.66 to 344.08 over the past decade. While the company's 10-year median is 69.94 vs. the industry median of 113.76, Atara Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current Days Payable of 281.11 is 147.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atara Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current Days Payable is 281.11, which is 302% above median its own 10-year median of 69.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.45 — trading 569.6% above its estimated fair value. The current Days Payable is 281.11, which is 302% above median its 10-year median of 69.94 and 147.1% above the Biotechnology industry median of 113.76. Atara Biotherapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Days Payable is 281.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (ATRA) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of $10.45 is trading 569.6% above its estimated GF Value™ of $1.56.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for ATRA:
Days Payable: 281.11 (302% above median its 10-year median of 69.94)
GF Value™: $1.56 vs. price of $10.45 (569.6% above fair value)
Industry Position: 147.1% above the Biotechnology median (#192 of 707)
No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
29GF Score
Get the complete analysis for ATRA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRA has been successfully added to your 
